A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC).
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have completed studies AMAC (NCT02589665) or AMBG (NCT03524092), received study drug, and did not stop study drug early
Female participants must agree to contraception requirements
Participants Must Not:
Participants must not have developed a new condition, including cancer, in the originator study
Participants must not have any important infections including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during either originator study
Participants must not have received surgery for UC in the originator study and must not be likely to require surgery for treatment of UC during this study
Participants must not have developed growths, known as polyps, that develop on the lining of the large intestine during the originator study that have not been removed prior to the start of this study
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo